4 results
To investigate in an unselected memory clinic sample, the clinical value of 18F]FBB PET in terms of1. change in diagnosis;2. change in level of confidence of diagnosis;3. impact on patient healthcare management.
Part I of this study is designed to identify the recommended phase 2 dose of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant colorectal carcinoma. Part II is designed to…
With this clinical study, we aim to gain more information about the pharmacological characteristics, safety profile, tolerability and efficacy of galunisertib in combination with capecitabine in patients with PM from CRC. The ultimate goal is to…
Investigate whether, in a routine clinical environment across a number of centers, the fabian-PRICO can adequately maintain oxygen saturation, with minimal staff intervention.